創薬科学研究科主催
第69回創薬科学セミナー
本セミナーは、先端薬科学特論・単位認定セミナーです。
日時 | 2017年09月27日水曜日・16:00~17:30 |
---|---|
場所 | 創薬科学研究館2階講義室 |
場所(URL) | http://www.ps.nagoya-u.ac.jp/access/ |
講師 | Dr. Scott D. Smid Ph.D.(Discipline of Pharmacology, School of Medicine, Faculty of Health Sciences The University of Adelaide/Deputy Head) |
連絡先 | 加藤竜司(kato-r@ps.nagoya-u.ac.jp) |
ファイル | 1505920340創薬科学セミナー9月27日69回.pptx |
Dr Scott Smid is a pharmacologist specializing in drug discovery and development research both in the pharmaceutical industry and academia. He maintains a strong research interest in experimental therapeutics applied towards novel treatments for neurodegenerative diseases.
In this talk he will discuss the bioactivity of natural products including a diverse range of plant polyphenolic compounds as templates in which to guide drug development, particularly in targeting misfolded proteins associated with brain pathologies occurring in dementia. Aggregation of toxic proteins such as beta amyloid and alpha synuclein occur in conditions such as Alzheimer’s and Parkinson’s disease, and plant polyphenolics can inhibit or ablate both the fibrillisation and aggregation of such proteins into off-target, benign states. He will provide insights into how this occurs and how this can guide urgently needed drug development for dementia and other medical applications, where targeting functional amyloids in nature can also be used to control microbial pathogens and viral infectivity.
In this talk he will discuss the bioactivity of natural products including a diverse range of plant polyphenolic compounds as templates in which to guide drug development, particularly in targeting misfolded proteins associated with brain pathologies occurring in dementia. Aggregation of toxic proteins such as beta amyloid and alpha synuclein occur in conditions such as Alzheimer’s and Parkinson’s disease, and plant polyphenolics can inhibit or ablate both the fibrillisation and aggregation of such proteins into off-target, benign states. He will provide insights into how this occurs and how this can guide urgently needed drug development for dementia and other medical applications, where targeting functional amyloids in nature can also be used to control microbial pathogens and viral infectivity.